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Bladder cancer (BCa) is the 7th most common cancer 
in men, with an estimated 81,190 new cases and 17,240 
deaths in 2018 in the USA (1). Radical cystectomy (RC) 
with cisplatin-based neoadjuvant chemotherapy (NAC) 
is the standard of care for the management of muscle-
invasive BCa (MIBC). In recent years, bladder-preserving 
strategies combining bladder tumor transurethral resection 
(TURB) with radiotherapy and concurrent radio-sensitizing 
chemotherapy, also known as trimodal therapy (TMT), have 
shown similar results and reduced morbidity as compared 
to RC in selected MIBC patients (2,3). As a result, current 
guidelines now recommend both RC and TMT as effective 
treatment options for MIBC (4-7). TMT is underutilized 
by most practitioners (8), mostly because of the difficulty 
in identifying appropriate patients that might benefit from 
this treatment. Therefore, the identification of molecular 
biomarkers that can predict TMT outcomes to guide its 
selection as a therapeutic choice is of utmost importance.
Efstathiou et al. (9) investigated the impact of molecular 
subtyping, immune and stromal infiltration on the outcomes 
after TMT or NAC and RC for MIBC. They found that, 
in the TMT group, increased tumor immune infiltration 
and IFN-γ signalling was associated with improved cancer-
specific survival. This was not the case for the NAC/
RC population. On the contrary, a stromal signature was 
associated with worse survival in the NAC/RC group, but 
not in the TMT group. Authors suggested a potential 
use for transcriptional profiling to guide the selection of 
patients who will benefit most from TMT.
Authors should be commended for the innovation and 
significance of their findings. Our increasing knowledge 
of the molecular and genomic features of BCa and their 
integration into clinical diagnostics pipelines denote the 
focus toward tailored approaches in MIBC.
Several tumor-related factors (T stage, hydronephrosis, 
carcinoma in situ) and treatment-related factors (TURB 
quality and complete response to induction chemotherapy 
or chemoradiation) have been associated with survival 
outcomes after TMT (3,10).  Nonetheless,  typical 
clinicopathological characteristics are often inadequate to 
predict survival outcomes or direct treatment choice. The 
discovery and validation of genomic biomarkers that predict 
response to various BCa treatments could be essential 
to guide tailored therapies based on a tumor’s molecular 
features (11).
In the recent literature, several studies have investigated 
biomarkers associated with radio/chemo outcomes and 
prognosis of TMT such as apoptosis-related biomarkers, 
cell proliferation-related biomarkers, receptor tyrosine 
kinases, DNA damage response-related biomarkers, 
hypoxia-related biomarkers, molecular subtypes, and 
immune checkpoint biomarkers (12). Very little is 
known about that role of the immune and stromal tumor 
infiltration as predictors for TMT outcomes.
In the metastatic BCa setting tumor infiltration by 
immune cells has been associated with response to immune 
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checkpoint inhibitors (13,14), but the role of tumor immune 
characteristics on response to TMT has been scantly 
evaluated. Efstathiou et al. (9) found that TMT-treated 
tumors with higher expression of genes associated with 
T-cell activation and IFN-γ signalling had better survival 
outcomes as compared with tumors with a lower signature 
score. This was not the case for patients treated with RC. 
Immune cells infiltration in BCa tissue before TMT may 
provide a more appropriate environment in which radiation 
can stimulate immune-mediated tumor killing through 
various mechanisms such as antigen release, chemokine 
secretion, or recruiting new immune cells (15,16). 
Additionally, the presence of fibroblasts in BCa has been 
linked with a T-cell exclusion phenotype and different grade 
of response to systemic therapy (13). Authors showed that 
high expression of a stromal signature was associated with 
worse survival after cystectomy, but not in the TMT cohort, 
suggesting that radiation could alter the treatment-resistant 
phenotype associated with stromal infiltration.
Activating T cell therapy has shown impressive results in 
various tumors, including BCa (17,18). This strategy aims to 
emancipate the immune system from the suppressive signals 
secreted by the tumor and promotes the identification of 
cancer cells as targets for killing (11). Given the association 
between radiation and immune activation, it is reasonable to 
speculate that a tumor immune infiltrate may be associated 
with an improved response to TMT. 
Although Efstathiou et al. (9) have performed a brilliant 
analysis to explore predictive factors for TMT outcomes, 
some limitations should be recognized.
NAC and induction chemotherapy regimens were 
different among protocols (yet primary cisplatin-based) 
(3,19). Since pathological and survival outcomes are 
different according to NAC regimes, the variability among 
study protocols might impact on oncologic outcomes for 
TMT and NAC/RC patients (20).
Smoking should always be taken into consideration when 
dealing with MIBC, as recent findings have revealed it 
might promote mechanisms of resistance to cisplatin-based 
chemotherapy in BCa patients. Pathologic response to 
cisplatin-based NAC was significantly affected by smoking 
status and smoking quantity in MIBC patients (21).
Baseline characteristics of patients were not balanced 
between groups, potentially affecting survival patterns. 
Moreover, rates of non-urothelial or mixed histologies and 
carcinoma in situ at TURB were not reported.
Authors used a narrow range of RT dosed among 
protocols (approximately between 64–65 Gy). It would 
be of great interest to investigate the effect of RT dose-
escalation in TMT considering the emerging role of image-
guided treatment and intensity-modulated RT that are 
characterized by improved target localization and reduced 
side effects.
In conclusion, it is crystal clear that precision medicine 
will play a predominant role in the management of MIBC in 
the next future, changing our focus from prognostication to 
prediction, with the need to elaborate modern classification 
systems that will take into account the nature of bladder 
cancer from a biological rather than histopathological 
perspective. Despite the continuous investigation of 
predictive biomarkers for guiding MIBC treatment choice, 
their integration into daily clinical practice requires strong 
validation in prospective clinical trials. While waiting for 
the results of ongoing clinical trials of TMT with or without 
PD-L1 inhibitors (e.g., SWOG/NRG 1806) that might 
further elucidate the association between immune infiltrate 
and radiation response, the study by Efstathiou et al. (9) 
deserves a prominent place in the current literature for the 
identification of immune and stromal tumor characteristics 
as biomarkers to guide the use of TMT.
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